Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
April 09, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09, 2024 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of...
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
April 09, 2024 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
BullFrog AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo
April 09, 2024 08:00 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., April 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...
Intermex Announces New Headquarters at the Datran Center, Miami-Dade
April 09, 2024 08:00 ET
|
International Money Express, Inc.
MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- Intermex, a global leader in the money transfer industry, announces the official relocation of its headquarters to the Datran Center in Miami-Dade, Florida....
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
April 09, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior...
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
April 09, 2024 08:00 ET
|
Tempest Therapeutics
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
April 09, 2024 08:00 ET
|
eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
April 09, 2024 08:00 ET
|
Candel Therapeutics
First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors from the enLIGHTEN™ Discovery...
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
April 09, 2024 08:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience...